This company has been acquired
Taro Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 6/6
Taro Pharmaceutical Industries has a total shareholder equity of $1.8B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $2.2B and $369.1M respectively. Taro Pharmaceutical Industries's EBIT is $7.3M making its interest coverage ratio -0.1. It has cash and short-term investments of $879.4M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -0.1x |
| Cash | US$879.35m |
| Equity | US$1.79b |
| Total liabilities | US$369.06m |
| Total assets | US$2.16b |
Recent financial health updates
Recent updates
Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity
Dec 12Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
Aug 16Taro Pharmaceutical: Potential Value In Sun Pharma Offer
Jun 02Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold
Feb 24Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M
Jan 24Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M
Oct 28Taro Pharmaceutical hits 52-week low; down 28% YTD
Aug 15Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M
Jul 27Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card
Jul 14We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative
Aug 03
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns
Jan 26
Financial Position Analysis
Short Term Liabilities: TARO's short term assets ($1.3B) exceed its short term liabilities ($361.1M).
Long Term Liabilities: TARO's short term assets ($1.3B) exceed its long term liabilities ($8.0M).
Debt to Equity History and Analysis
Debt Level: TARO is debt free.
Reducing Debt: TARO had no debt 5 years ago.
Debt Coverage: TARO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TARO has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/24 03:43 |
| End of Day Share Price | 2024/06/24 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Randall Stanicky | Goldman Sachs |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Kenneth Cacciatore | TD Cowen |